fluphenazine has been researched along with Basal Ganglia Diseases in 90 studies
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The introduction of the atypical neuroleptic, clozapine, has had widespread influence not only on the treatment of the seriously mentally ill patient, but also on new drug development and on hypotheses of the pathophysiology of schizophrenia." | 9.07 | Predictors of clozapine response in schizophrenia. ( Hsiao, JK; Litman, RE; Owen, RR; Pickar, D; Su, TP, 1994) |
| "Fluphenazine was significantly effective in treating symptoms such as emotional withdrawal, blunted affect, suspiciousness, thought disturbances, but not hallucinations." | 5.28 | Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. ( Altamura, AC; Girardi, T; Mauri, MC; Panetta, B, 1990) |
| "The introduction of the atypical neuroleptic, clozapine, has had widespread influence not only on the treatment of the seriously mentally ill patient, but also on new drug development and on hypotheses of the pathophysiology of schizophrenia." | 5.07 | Predictors of clozapine response in schizophrenia. ( Hsiao, JK; Litman, RE; Owen, RR; Pickar, D; Su, TP, 1994) |
| "This study evaluated the feasibility and impact of gradually reducing relatively high doses of fluphenazine decanoate by one-half for chronically impaired, poor inner-city patients with schizophrenia." | 5.07 | A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. ( Egan, GJ; Gloersen, BA; Inderbitzin, LB; Lewine, RR; Scheller-Gilkey, G; Swofford, CD; Vidanagama, BP; Waternaux, C, 1994) |
| "These results do not indicate an association between plasma fluphenazine levels and response to treatment or extrapyramidal side effects in first-episode schizophrenia." | 5.07 | Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients. ( Alvir, J; Chakos, M; Cooper, T; Kane, J; Koreen, AR; Lieberman, J; Loebel, A, 1994) |
| "Fifty-three patients with acute exacerbations of Research Diagnostic Criteria schizophrenic, schizoaffective (mainly schizophrenic), and other nonaffective psychoses completed 24 or 28 days of treatment with randomized, fixed, double-blind doses of 10, 20, or 30 mg of oral fluphenazine hydrochloride daily." | 5.06 | Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. ( Jain, A; Levinson, DF; Silver, P; Simpson, GM; Singh, H; Stephanos, MJ; Yadalam, K, 1990) |
| "Fifty-seven patients with a diagnosis of schizophrenia were started on either fluphenazine decanoate or flupenthixol decanoate injections in a double-blind trial just prior to discharge into the community." | 5.04 | Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. ( Hirsch, SR; Knights, A; Okasha, MS; Salih, MA, 1979) |
| "We present a patient with schizophrenia who developed acute and persistent extrapyramidal symptoms requiring tracheostomy and long-term rehabilitation after long-acting injections of fluphenazine decanoate." | 3.88 | Long-acting formulation leading to severe long-term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms. ( Matsunaga, H; Mitsui, Y; Omi, T, 2018) |
| "The risk of adverse side effects of neuroleptic agents must be considered carefully in the treatment of acute and long-term psychotic states." | 3.75 | Antipsychotic drug side effects: their relationship to dose. ( Kane, JM, 1985) |
| "A patient with chronic schizophrenia treated with fluphenazine developed neuroleptic malignant syndrome, characterized by fever, obtundation, rigidity, and tremulousness." | 3.66 | Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. ( Adler, S; Coyle, J; Granato, JE; Karim, AH; Krumholz, A; Ringel, A; Stern, BJ, 1983) |
| "Injected intramuscularly, the enanthane and decanoate esters of the phenothiazine fluphenazine are an effective treatment of the disordered behavior and thinking of schizophrenia." | 3.65 | The long-acting phenothiazines. ( Groves, JE; Mandel, MR, 1975) |
| "Oral fluphenazine was given in fixed, randomized, double-blind doses (10, 20, or 30 mg/day) for 4 weeks to 72 inpatients with acute schizophrenic exacerbations." | 2.68 | Fluphenazine plasma levels, dosage, efficacy, and side effects. ( Cooper, TB; Levinson, DF; Lo, ES; Simpson, GM; Singh, H; Stephanos, MJ; Yadalam, K, 1995) |
| "Acute withdrawal is therefore unjustified, but occasional revision of dosage of anti-Parkinsonian drugs is advisable." | 2.64 | Benzhexol and side effects with long-acting fluphenazine therapy. ( Crammer, JL; Grove, L, 1972) |
| " It is suggested that additional studies, carefully designed, on dosage and plasma levels could help in achieving the lowest possible therapeutic dosage and thus in minimizing side effects." | 2.37 | Blood levels of neuroleptics: state of the art. ( Simpson, GM; Yadalam, K, 1985) |
| "Fluphenazine was significantly effective in treating symptoms such as emotional withdrawal, blunted affect, suspiciousness, thought disturbances, but not hallucinations." | 1.28 | Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. ( Altamura, AC; Girardi, T; Mauri, MC; Panetta, B, 1990) |
| " The authors examined the possibilities of a pharmacokinetic effect of alprazolam on neuroleptic plasma levels and of a clinical effect of alprazolam." | 1.28 | Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. ( Angrist, B; Cooper, T; Douyon, R; Peselow, E; Rotrosen, J, 1989) |
| " Such variations have been attributed to individual metabolism, pharmacologic differences, and age--all of which may need careful consideration in prescribing an appropriate dosage regimen for a given patient." | 1.27 | Interpatient variations in antipsychotic therapy. ( Gershon, S; McIntyre, IM, 1985) |
| " The data suggest that neither prophylactic nor long-term use of antiparkinsonian agents is necessary for most patients receiving fluphenazine decanoate." | 1.26 | Antiparkinsonian agents and fluphenazine decanoate. ( Idzorek, S, 1976) |
| " In view of current interest in depot psychopharmaceuticals, they recommend that careful attention be given to dosage and administration schedules and to the possibility of delayed pseudoparkinsonian symptoms." | 1.25 | Delayed severe extrapyramidal disturbance following frequent depot phenothiazine administration. ( Warner, AM; Wyman, SM, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 73 (81.11) | 18.7374 |
| 1990's | 13 (14.44) | 18.2507 |
| 2000's | 3 (3.33) | 29.6817 |
| 2010's | 1 (1.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Omi, T | 1 |
| Mitsui, Y | 1 |
| Matsunaga, H | 1 |
| KRUSE, W | 2 |
| Pivac, N | 1 |
| Kozaric-Kovacic, D | 1 |
| Muck-Seler, D | 1 |
| Brashier, M | 1 |
| Giugni, EA | 1 |
| Boddy, RS | 1 |
| Limet, NG | 1 |
| Chouinard, G | 2 |
| Annable, L | 1 |
| Ross-Chouinard, A | 1 |
| Kane, JM | 2 |
| Woerner, M | 1 |
| Weinhold, P | 1 |
| Wegner, J | 1 |
| Kinon, B | 1 |
| Caroff, S | 2 |
| Rosenberg, H | 2 |
| Gerber, JC | 2 |
| Dencker, SJ | 2 |
| Knezevic, W | 1 |
| Mastaglia, FL | 1 |
| Lefroy, RB | 1 |
| Fisher, A | 1 |
| Glazer, WM | 1 |
| Granato, JE | 1 |
| Stern, BJ | 1 |
| Ringel, A | 1 |
| Karim, AH | 1 |
| Krumholz, A | 1 |
| Coyle, J | 1 |
| Adler, S | 1 |
| Shu, L | 1 |
| Magnus, RV | 1 |
| Dysken, MW | 1 |
| Javaid, JI | 1 |
| Chang, SS | 1 |
| Schaffer, C | 1 |
| Shahid, A | 1 |
| Davis, JM | 1 |
| Blum, A | 1 |
| Witschy, JK | 1 |
| Redmond, FC | 1 |
| Pickar, D | 1 |
| Owen, RR | 1 |
| Litman, RE | 1 |
| Hsiao, JK | 1 |
| Su, TP | 1 |
| Johnson, AE | 1 |
| Liminga, U | 1 |
| Lidén, A | 1 |
| Lindefors, N | 1 |
| Gunne, LM | 1 |
| Wiesel, FA | 1 |
| Levinson, DF | 2 |
| Simpson, GM | 3 |
| Lo, ES | 1 |
| Cooper, TB | 1 |
| Singh, H | 2 |
| Yadalam, K | 3 |
| Stephanos, MJ | 2 |
| Hogarty, GE | 1 |
| McEvoy, JP | 2 |
| Ulrich, RF | 1 |
| DiBarry, AL | 1 |
| Bartone, P | 1 |
| Cooley, S | 1 |
| Hammill, K | 1 |
| Carter, M | 1 |
| Munetz, MR | 1 |
| Perel, J | 1 |
| Harasko-van der Meer, C | 1 |
| Brücke, T | 1 |
| Wenger, S | 1 |
| Fischer, P | 1 |
| Deecke, L | 1 |
| Podreka, I | 1 |
| Bransgrove, LL | 1 |
| Kelly, MW | 1 |
| Inderbitzin, LB | 1 |
| Lewine, RR | 1 |
| Scheller-Gilkey, G | 1 |
| Swofford, CD | 1 |
| Egan, GJ | 1 |
| Gloersen, BA | 1 |
| Vidanagama, BP | 1 |
| Waternaux, C | 1 |
| Burke, MA | 1 |
| Ritchie, JC | 1 |
| Koreen, AR | 1 |
| Lieberman, J | 1 |
| Alvir, J | 1 |
| Chakos, M | 1 |
| Loebel, A | 1 |
| Cooper, T | 2 |
| Kane, J | 3 |
| Ketai, R | 1 |
| Mason, AS | 1 |
| Granacher, RP | 1 |
| Mindham, RH | 2 |
| Johnson, DA | 2 |
| Dumont, A | 1 |
| Minjat, M | 1 |
| Blanc, JL | 1 |
| Vignon, H | 1 |
| Schilkrut, R | 1 |
| Duran, E | 1 |
| Haverbeck, C | 1 |
| Katz, I | 1 |
| Vidal, P | 1 |
| Rifkin, A | 3 |
| Quitkin, F | 3 |
| Klein, DF | 3 |
| Obukhov, GA | 1 |
| Groves, JE | 1 |
| Mandel, MR | 2 |
| Gelenberg, AJ | 1 |
| Doller, JC | 1 |
| Schooler, NR | 1 |
| Mieske, M | 1 |
| Severe, J | 1 |
| Knights, A | 1 |
| Okasha, MS | 1 |
| Salih, MA | 1 |
| Hirsch, SR | 1 |
| Jose, C | 1 |
| Mallya, A | 1 |
| Mehta, D | 1 |
| Evenson, R | 1 |
| Holland, R | 1 |
| Caroli, F | 1 |
| Littre-Poirier, MF | 1 |
| Ginestet, D | 1 |
| Deniker, P | 1 |
| Fry, AH | 1 |
| Beard, AW | 1 |
| Carney, MW | 2 |
| Sheffield, BF | 2 |
| Ayd, FJ | 3 |
| Haslam, MT | 1 |
| Bromham, BM | 1 |
| Schiff, AA | 1 |
| Swett, C | 1 |
| Marriett, PF | 1 |
| Warner, AM | 1 |
| Wyman, SM | 1 |
| Fontaine, R | 1 |
| Van Putten, T | 2 |
| Mutalipassi, LR | 2 |
| Idzorek, S | 1 |
| Stimmel, GL | 1 |
| Chakos, MH | 1 |
| Mayerhoff, DI | 1 |
| Loebel, AD | 1 |
| Alvir, JM | 1 |
| Lieberman, JA | 1 |
| Altamura, AC | 1 |
| Mauri, MC | 1 |
| Girardi, T | 1 |
| Panetta, B | 1 |
| Jain, A | 1 |
| Silver, P | 1 |
| Douyon, R | 1 |
| Angrist, B | 1 |
| Peselow, E | 1 |
| Rotrosen, J | 1 |
| Keshavan, MS | 1 |
| Kambhampati, RK | 1 |
| McIntyre, IM | 1 |
| Gershon, S | 1 |
| Dilsaver, SC | 1 |
| Sachdev, PS | 1 |
| Frankenberg, K | 1 |
| Malm, U | 1 |
| Zell, B | 1 |
| Safer, DJ | 1 |
| Allen, RP | 1 |
| Stern, P | 1 |
| Valjevac, K | 1 |
| Snyder, SH | 1 |
| Greenberg, D | 1 |
| Yamumura, HI | 1 |
| Routsonis, KG | 1 |
| Photiadis, H | 1 |
| Ladhani, FM | 1 |
| Grove, L | 1 |
| Crammer, JL | 1 |
| Chien, CP | 2 |
| Cole, JO | 2 |
| Gaind, R | 1 |
| Anstee, BH | 1 |
| Rimmer, L | 1 |
| Malkin, MD | 1 |
| Angst, J | 1 |
| Frei, M | 1 |
| Dreyfuss, J | 1 |
| Beer, B | 1 |
| Devine, DD | 1 |
| Roberts, BF | 1 |
| Schreiber, EC | 1 |
| Schwingenheuer, J | 1 |
| Meltzer, HY | 1 |
| Dimascio, A | 1 |
| Donlon, PT | 1 |
| Tupin, JP | 1 |
| Dillon, JB | 1 |
| Svestka, J | 1 |
| Náhunek, K | 1 |
| Bastecký, J | 1 |
| Vinar, O | 1 |
| Taussigová, D | 1 |
| Kernohan, GA | 1 |
| Allan, RN | 1 |
| White, HC | 1 |
6 reviews available for fluphenazine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Depot fluphenazine: risk/benefit ratio.
Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Fe | 1984 |
The depot fluphenazines: a reappraisal after 10 years' clinical experience.
Topics: Administration, Oral; Adult; Age Factors; Aged; Ambulatory Care; Basal Ganglia Diseases; Child; Dela | 1975 |
Antipsychotic drug side effects: their relationship to dose.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Respon | 1985 |
Blood levels of neuroleptics: state of the art.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Drug | 1985 |
Antipsychotic medication: clinical guidelines for maintenance therapy.
Topics: Administration, Oral; Ambulatory Care; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Dise | 1985 |
Side effects of depot fluphenazines.
Topics: Agranulocytosis; Barbiturates; Basal Ganglia Diseases; Benztropine; Biperiden; Delayed-Action Prepar | 1974 |
26 trials available for fluphenazine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Response Relationship, Dr | 2004 |
Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Doub | 1982 |
Depot fluphenazine: risk/benefit ratio.
Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Fe | 1984 |
Fluphenazine pharmacokinetics and therapeutic response.
Topics: Acetylation; Adult; Basal Ganglia Diseases; Female; Fluphenazine; Humans; Kinetics; Male; Schizophre | 1981 |
Predictors of clozapine response in schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Double-Blind Method; Female; Fluphen | 1994 |
Fluphenazine plasma levels, dosage, efficacy, and side effects.
Topics: Acute Disease; Administration, Oral; Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Dose-Re | 1995 |
Pharmacotherapy of impaired affect in recovering schizophrenic patients.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Anxiety Disorders; Basal Ganglia Diseases; | 1995 |
A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Topics: Adult; Ambulatory Care; Basal Ganglia Diseases; Chronic Disease; Delayed-Action Preparations; Double | 1994 |
Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Basal Ganglia Diseases; Chronic Disease; Drug Administ | 1994 |
Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as T | 1976 |
[Course of psychopathologic and extrapyramidal motor symptoms during long-term treatment of schizophrenic patients with psycholeptic drugs (author's transl)].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Fem | 1978 |
Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data.
Topics: Administration, Oral; Aftercare; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Fluph | 1977 |
Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data [proceedings].
Topics: Basal Ganglia Diseases; Clinical Trials as Topic; Female; Fluphenazine; Humans; Male; Placebos; Recu | 1977 |
Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Dose-Response Rela | 1979 |
Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Depression; Flupenthixol; | 1979 |
[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Fluph | 1975 |
A comparative trail of fluphenazine decanoate and flupenthixol decanoate.
Topics: Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Decanoic Acids; Drug Evaluation; Etha | 1975 |
Haloperidol in psychiatry.
Topics: Anxiety Disorders; Basal Ganglia Diseases; Clinical Trials as Topic; Dopamine Antagonists; Fluphenaz | 1975 |
Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.
Topics: Acute Disease; Akathisia, Drug-Induced; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Dr | 1990 |
Antipsychotic drug side effects: their relationship to dose.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Respon | 1985 |
A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as | 1973 |
Benzhexol and side effects with long-acting fluphenazine therapy.
Topics: Administration, Oral; Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Female; Fluphen | 1972 |
Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antiparkinson Agents; Basal Ganglia Diseases | 1973 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; F | 1972 |
Phenothiazine-induced decompensation.
Topics: Adult; Affective Symptoms; Basal Ganglia Diseases; Biperiden; Clinical Trials as Topic; Dose-Respons | 1974 |
[The depot neuroleptic agent fluspirilene (author's transl)].
Topics: Basal Ganglia Diseases; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Female; Fluoroben | 1973 |
60 other studies available for fluphenazine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Long-acting formulation leading to severe long-term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms.
Topics: Basal Ganglia Diseases; Female; Fluphenazine; Humans; Middle Aged; Patient Compliance; Schizophrenia | 2018 |
The relationsip between the anti-hallucinatory effect and extrapyramidal symptoms induced by fluphenazine. (A study in 40 chronic schizophrenics).
Topics: Basal Ganglia Diseases; Extrapyramidal Tracts; Fluphenazine; Hallucinations; Humans; Schizophrenia; | 1961 |
[OBSERVATIONS ON 140 SCHIZOPHRENICS TREATED WITH FLUPHENAZINE. WITH SPECIAL REFERENCE TO DRUG-INDUCED EXTRAPYRAMIDAL SYNDROMES].
Topics: Basal Ganglia Diseases; Extrapyramidal Tracts; Fluphenazine; Humans; Movement Disorders; Parkinsonia | 1963 |
Fluphenazine-induced extrapyramidal side effects in a horse.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Diphenhydramine; Extrapyramidal Tracts; Fluph | 2006 |
Mis-deca-n identity?
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dystonia; Fluphenazine; Humans; Male; Substance | 2007 |
A prospective study of tardive dyskinesia development: preliminary results.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Fem | 1982 |
Neuroleptic malignant syndrome and malignant hyperthermia.
Topics: Adult; Basal Ganglia Diseases; Diagnosis, Differential; Female; Fever; Fluphenazine; Humans; Maligna | 1983 |
Neuroleptic malignant syndrome and malignant hyperthermia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Fever; Fluphenazine; Halothane; Humans; Musc | 1983 |
The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
Topics: Administration, Oral; Antipsychotic Agents; Basal Ganglia Diseases; Biological Availability; Chronic | 1984 |
Neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Female; Fever; Fluphenazine; Haloperidol; Humans; Male | 1984 |
Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine.
Topics: Adult; Basal Ganglia Diseases; Bromocriptine; Dantrolene; Drug Therapy, Combination; Fluphenazine; H | 1983 |
[Double-blind study of domestic penfluridol and fluphenazine decanoate].
Topics: Adolescent; Adult; Basal Ganglia Diseases; Double-Blind Method; Fluphenazine; Humans; Male; Middle A | 1983 |
[Fluspirilen and fluphenazine in schizophrenic patients. Comparative study].
Topics: Basal Ganglia Diseases; Delayed-Action Preparations; Female; Fluphenazine; Fluspirilene; Humans; Mal | 1980 |
Patients at risk of developing severe side effects from depot fluphenazine treatment.
Topics: Adult; Basal Ganglia Diseases; Delayed-Action Preparations; Fluphenazine; Humans; Male; Risk; Schizo | 1980 |
Extrapyramidal reaction to fluphenazine potentiated by thyrotoxicosis.
Topics: Basal Ganglia Diseases; Diphenhydramine; Drug Therapy, Combination; Fluphenazine; Humans; Hyperthyro | 1981 |
Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Autoradiogr | 1994 |
Two cases of long term dopamine D2 receptor blockade after depot neuroleptics.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Dopamine D2 Receptor Anta | 1993 |
Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Female; Fluphenazine; | 1994 |
A pilot study of a structured interview addressing sexual function in men with schizophrenia.
Topics: Adult; Basal Ganglia Diseases; Fluphenazine; Haloperidol; Hospitalization; Humans; Libido; Male; Mas | 1994 |
Interaction between fluoxetine and neuroleptics.
Topics: Akathisia, Drug-Induced; Basal Ganglia Diseases; Drug Interactions; Fluoxetine; Fluphenazine; Humans | 1993 |
Basic principles of rapid neuroleptization.
Topics: Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Fluphenazine; Ha | 1976 |
Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Basal Ganglia Diseases; Depression; Drug Implants; Fluph | 1977 |
[Malignant syndrome caused by neuroleptics (3 observations)].
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Creatine Kinase; Female; Fluphenazine; Humans; | 1978 |
[Prolonged action neuroleptics (review of the foreign literature)].
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Child; Chronic Diseas | 1975 |
The long-acting phenothiazines.
Topics: Antiparkinson Agents; Basal Ganglia Diseases; Cholestasis; Community Mental Health Services; Decanoa | 1975 |
Iatrogenic morbidity in patients taking depot fluphenazine.
Topics: Adult; Age Factors; Aged; Akathisia, Drug-Induced; Basal Ganglia Diseases; Delayed-Action Preparatio | 1979 |
Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Basal Ganglia Diseases; Decanoates; Del | 1978 |
Iatrogenic extrapyramidal syndrome--a cautionary tale.
Topics: Adult; Basal Ganglia Diseases; Fluphenazine; Humans; Iatrogenic Disease; Male | 1977 |
Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Delayed-Action Preparations; Depression; Female; Fl | 1976 |
Therapy with injectable fluphenazines.
Topics: Acute Disease; Age Factors; Ambulatory Care; Basal Ganglia Diseases; Chronic Disease; Delayed-Action | 1976 |
Drug-induced dystonia.
Topics: Adjustment Disorders; Adult; Basal Ganglia Diseases; Chlorpromazine; Chlorprothixene; Female; Fluphe | 1975 |
Letter: Potentiation of tardive dyskinesia: possible drug interaction.
Topics: Basal Ganglia Diseases; Benztropine; Drug Synergism; Fluphenazine; Humans; Movement Disorders; Tropa | 1975 |
Delayed severe extrapyramidal disturbance following frequent depot phenothiazine administration.
Topics: Adult; Basal Ganglia Diseases; Delayed-Action Preparations; Drug Administration Schedule; Emergency | 1975 |
Letter: Fluphenazine with other antipsychotic drugs.
Topics: Basal Ganglia Diseases; Chlorpromazine; Drug Administration Schedule; Drug Therapy, Combination; Flu | 1975 |
Fluphenazine enanthate induced decompensations.
Topics: Adult; Basal Ganglia Diseases; Biperiden; Female; Fluphenazine; Humans; Male; Schizophrenia | 1975 |
Antiparkinsonian agents and fluphenazine decanoate.
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Decanoates; Depressive Disorder, Major; Fluphen | 1976 |
Neuroleptics and the corpus striatum: clinical implications.
Topics: Acetylcholine; Basal Ganglia Diseases; Benztropine; Corpus Striatum; Dopamine; Fluphenazine; Haloper | 1976 |
Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Female; Fluphenazine; Humans; Incidence; M | 1992 |
Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Topics: Aged; Basal Ganglia Diseases; Blood Pressure; Electrocardiography; Electroencephalography; Female; F | 1990 |
Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Topics: Adult; Alprazolam; Antipsychotic Agents; Basal Ganglia Diseases; Drug Synergism; Drug Therapy, Combi | 1989 |
Prolonged fever without extrapyramidal symptoms during neuroleptic treatment.
Topics: Adult; Basal Ganglia Diseases; Fluphenazine; Humans; Male; Neuroleptic Malignant Syndrome; Schizophr | 1989 |
Interpatient variations in antipsychotic therapy.
Topics: Age Factors; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationshi | 1985 |
Effects of neuroleptics on body temperature.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Biperiden; Body Temperature; Dibenzothiepins; | 1988 |
Lithium potentiation of neuroleptic-related extrapyramidal side effects.
Topics: Adult; Basal Ganglia Diseases; Bipolar Disorder; Drug Synergism; Drug Therapy, Combination; Female; | 1986 |
The effect of fluphenazine in psychologically normal volunteers: some temporal, performance, and biochemical relationships.
Topics: Adult; Basal Ganglia Diseases; Cholinesterases; Cognition; Dose-Response Relationship, Drug; Fluphen | 1971 |
The effect of phenothiazines on botulinus intoxication.
Topics: Animals; Antitoxins; Arachnida; Basal Ganglia Diseases; Botulinum Toxins; Botulism; Butyrophenones; | 1974 |
Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Binding, Competitive; Brain; Chlorpromazine; | 1974 |
The use of fluphenazine enanthate in psychotic patients.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Female; Fluphenazine; Humans; Male; Schizophrenia | 1973 |
The long-term maintenance treatment of schizophrenic out-patients with depot flupenthixol.
Topics: Basal Ganglia Diseases; Bipolar Disorder; Catatonia; Depression; Female; Fluphenazine; Hospitalizati | 1973 |
Letter: Severe extrapyramidal manifestations following fluphenazine overdose.
Topics: Adult; Basal Ganglia Diseases; Fluphenazine; Humans; Male | 1974 |
Fluphenazine-induced parkinsonism in the baboon: pharmacological and metabolic studies.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Carbon Isotopes; Chromatography, Thin Layer; Feces; Fe | 1972 |
[Clinical experiences with a delayed-action preparation of fluphenazine].
Topics: Administration, Oral; Adult; Aged; Basal Ganglia Diseases; Bipolar Disorder; Climacteric; Delayed-Ac | 1972 |
Rigidity, hyperpyrexia and coma following fluphenazine enanthate.
Topics: Adult; Basal Ganglia Diseases; Benztropine; Catatonia; Coma; Creatine Kinase; Female; Fever; Fluphen | 1973 |
Antiparkinsonian agents and depot phenothiazine.
Topics: Adult; Age Factors; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Female; Fluphenazine; | 1974 |
Rapid "digitalization" of decompensated schizophrenic patients with antipsychotic agents.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Community Me | 1974 |
Parenteral long-acting phenothiazines.
Topics: Basal Ganglia Diseases; Fever; Fluphenazine; Haloperidol; Humans; Male; Middle Aged | 1972 |
Flupenthixol depot in the maintenance treatment of psychoses.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Butyrophenones; Delayed-Action Preparations; Ethano | 1972 |
Extrapyramidal symptoms in the course of fluphenazine treatment.
Topics: Adult; Basal Ganglia Diseases; Delayed-Action Preparations; Female; Fluphenazine; Humans; Male; Move | 1972 |
Long-acting phenothiazine preparations in the treatment of schizophrenia.
Topics: Basal Ganglia Diseases; Delayed-Action Preparations; Depression; Fluphenazine; Humans; Injections, I | 1972 |
Side effects of parenteral long-acting phenothiazines.
Topics: Adult; Basal Ganglia Diseases; Body Temperature Regulation; Fluphenazine; Humans; Hypothalamus; Male | 1972 |